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and total cholesterol was only 2.96. In contrast, a US study by Hopkins
et al (1) found an odds ratio for CAD of 13.8 (p 5 1.0 3 1027) for a
combination of Lp(a) .40 mg/dL and total cholesterol .260 mg/dL (a
fourfold higher value than that found by Cantin et al). The US study
involved 124 men and 46 women with premature CAD (,age 55 in
men and ,65 in women). CAD in all cases was documented by a
history of myocardial infarction, percutaneous transluminal coronary
angioplasty, or coronary artery bypass graft.
Many investigators have also neglected the interaction between
Lp(a) and other lipid and nonlipid CAD risk factors. In the US (1) the
presence of Lp(a) .40 mg/dL increased the risk associated with
cigarette smoking by a factor of 1.9, diabetes by a factor of 3.4, elevated
total cholesterol levels by a factor of 4.2, hypertension by a factor of
4.6, high total/HDL cholesterol ratio by a factor of 6.9, and high
homocysteine levels by a factor of 9.3. The presence of three or more
risk factors was associated with a relative risk of 43 (p , 0.0001) when
Lp(a) was .40 mg/dL, compared with a relative risk of 13 (p , 0.0001)
when Lp(a) was ,40 mg/dL.
Another striking finding in the US study (1) was the markedly
increased risk of CAD with elevated total/HDL cholesterol ratio.
Among those with Lp(a) .40 mg/dL, the odds ratio for CAD was 35
(p , 1.0 3 1027) when total/HDL cholesterol ratio was .5.8 versus
13.8 when total cholesterol level was .260 mg/dL. Among those with
high total/HDL cholesterol ratio and high Lp(a), the incremental risks
associated with additional coronary risk factors were more than
synergistic. For example, the odds ratio increased to 122 (p , 1.0 3
10212) in the combined presence of Lp(a) .40 mg/dL, total/HDL
cholesterol ratio of .5.8, and two or more nonlipid risk factors. For
comparison, in the Framingham Heart Study (7) the odds ratio for
CAD was only 20 when all the six risk factors, elevated cholesterol, low
HDL, diabetes, cigarette smoking, high blood pressure, and left
ventricular hypertrophy, were present. However, the odds ratio de-
creased to 1.3 when the total/HDL cholesterol ratio was ,5.8 and
other risk factors were absent, underscoring the importance of con-
comitant risk factors.
Solymoss et al. (8) have corroborated the crucial role of elevated
total/HDL ratio in markedly increasing the risk of CAD with elevated
Lp(a). They found a 100-fold risk of CAD in women when the
total/HDL cholesterol ratio was .5.8 and Lp(a) was .55 mg/dL versus
a total/HDL cholesterol ratio of ,4 and Lp(a) of ,15 mg/dL. These
data indicate that the CAD risk from elevated Lp(a) is greater with
elevated total/HDL cholesterol ratio than with elevated total choles-
terol. Since a high total/HDL cholesterol ratio is often due to low
HDL, those with elevated Lp(a) and low HDL cholesterol may be at
markedly increased risk of CAD, even if LDL is not excessively
elevated. Asian Indians appear to be such a population. They have the
highest rate of premature CAD, although they have low prevalence of
conventional risk factors, and nearly half of them are lifelong vegetar-
ians (9). Synergistic adverse effects of elevated Lp(a) with other
lipoproteins have been invoked to explain this excess burden of CAD
in Asian Indians (10). Elevated Lp(a) (.30 mg/dL) is found in 23–50%
of Asian Indians, but only 15% of Whites worldwide (11). Yet, the
population-attributable risk of premature CAD in the Framingham
Heart Study was similar to that of elevated total cholesterol (6).
However, this risk may vary in different populations since Lp(a) levels
vary markedly among people of different ethnic origin (10).
We have recently examined the association of Lp(a) and the
presence of chlamydia in coronary atherosclerosis in 60 autopsy
specimens (12). Of the 42 cases with severe atherosclerosis, 36 were
immunopositive for chlamydia, compared with 1 of 18 with mild
atherosclerosis (p , 0.001). Lp(a) levels were 19.9 6 4.4 mg/dL in
severe atherosclerosis versus 6.1 6 1.2 mg/dL in mild atherosclerosis
(p , 0.04). There was no correlation of the severity of atherosclerosis
with other lipids. In addition, we found that 48% of the cases with
severe atherosclerosis were positive for HLA class II genotype 13 or 17
as compared with 20% of cases with mild atherosclerosis (p , 0.01).
These results indicate a close association of Lp(a) abnormality with
chlamydia infection and certain genetic predisposition.
While we debate whether Lp(a) is an independent risk factor or
not, we should not lose sight of the fact that Lp(a) is a powerful and
important risk factor for CAD, particularly when total/HDL choles-
terol ratio is high. From a therapeutic perspective, niacin has been
shown to reduce the total/HDL ratio and Lp(a) levels by as much as
30% (13), with similar or greater reductions in LDL, when used in
combination with statins. Thus, in both primary and secondary pre-
vention, aggressive lipid-lowering therapy using a combination of
niacin and statins, aimed at lowering total/HDL ratio as well as LDL,
appears to be a viable strategy to reduce the markedly elevated risk
from elevated Lp(a), although evidence of benefit from randomized
clinical trials is yet to be reported.
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Reply
I am in total agreement with Drs. Enas and Mehta when they state that
lipoprotein (a) [Lp(a)] enhances the risk associated with other lipid
and nonlipid risk factors for ischemic heart disease. However, I do not
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believe that our conclusion suggesting that Lp(a) by itself is not a risk
factor for ischemic heart disease (1) is erroneous. Although some
prospective population-based studies have found Lp(a) to be an
independent risk factor for ischemic heart disease (2,3), we must bear
in mind that the bulk of the data supporting that conclusion is derived
from case-control studies. The studies of Hopkins et al. (4) and
Orth-Gome´r et al. (5), which are mentioned by Drs. Enas and Metha,
fall into that category. In the former, 160 young subjects with docu-
mented ischemic heart disease were matched to 165 control subjects. A
subgroup of 27 patients and five control subjects with elevated Lp(a)
and total cholesterol had a relative risk of 13.8 of developing ischemic
heart disease (4). Although this may look extremely impressive when
compared with our risk of 2.96 (1), I do not think that the two studies
can be compared. Our study is prospective, population based with at
least 215 subjects in each subgroup of analysis. These numbers alone
can account for the differences. The latter study, also case-control, is a
study of women younger than 65 years (5). Risk factors for this group
are different than those for the men in our study. The inherent
selection biases associated with case-control studies will favor the
inclusion of subjects with altered lipid profiles as well as other ischemic
heart disease risk factors. Therefore, these data should be interpreted
with caution.
The PROCAM study is also a population-based prospective co-
hort; in the report of Assmann et al. (6) there is a significant risk of
ischemic heart disease associated with elevated Lp(a). However, it
must not be forgotten that in that particular report, only 863 of the
4381 participants included had Lp(a) measurements. I do not want to
underestimate the importance Lp(a) may have in ischemic heart
disease; it is clearly a risk factor when associated with other risk
factors. However, I still think that there is a lack of prospective
population based studies supporting a role for Lp(a) as an independent
risk factor. Considering this, I do not think that Lp(a) measurements
should be carried out in a primary prevention setting.
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Functional Assessment of Coronary Stenoses
I read the article by Bech et al. regarding deferral of angioplasty on
intermediate coronary stenoses based on measured coronary flow
reserve with interest (1). The authors addressed an important issue,
that of interventional revascularization procedures being performed
on obstructive lesions of “intermediate” severity by angiography
without objective evidence of ischemia and therefore uncertain influ-
ence on outcome.
I take issue, however, with the statement in the conclusion of their
article, that deferral of PTCA based on FFRmyo is safe “irrespective of
the noninvasive stress test result.” If the authors are considering stress
ECG testing, their statement may be correct as it is known that
abnormalities on treadmill tolerance tests do not correlate well with
functional severity of coronary lesions. Stress nuclear perfusion scin-
tigraphy, with either thallium or technetium based agents, however, is
reflective of the functional significance of an underlying stenosis. Dr.
N. Pijls (one of the authors of the present study), nicely demonstrated
in an earlier paper the strong relationship between an FFRmyo ,0.75
and ischemia demonstrated either by stress thallium scintigraphy or
dobutamine echocardiography (2). This study, in fact, used the nonin-
vasive test results as the reference standard as three patients of 211
with FFR $0.75 were said to have “false negative results” as their
stress tests were positive.
It is also widely appreciated that provocative testing with nuclear or
echocardiographic imaging have quite good positive predictive values
regarding future coronary events. An original study by K. Brown
showed in a series of 100 patients that compared with clinical, stress
ECG, and angiographic data, the best predictor of future events was
the number of segments with reversible thallium defects (3).
Therefore, if the authors use of the term “noninvasive stress test”
includes the above-described imaging modalities, I would be interested
in seeing more data before abandoning such diagnostic techniques.
Although all noninvasive testing modalities for detecting coronary
artery disease have less than optimal sensitivity and specificity depend-
ing on the patient population, I don’t feel the evidence is there to
support the use of intracoronary pressure recording in favor of “stress
testing”.
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Reply
We appreciate the comments of Dr. Miller, which give us the oppor-
tunity to clarify the use of coronary pressure and fractional flow
reserve in case of intermediate stenosis.
Generally, we believe that a decision to perform myocardial
revascularization should be based upon objective proof of inducible
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